267230-40-0Relevant academic research and scientific papers
TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
-
Paragraph 00437-00438, (2021/12/08)
The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.
CC chemokine receptor-3 (CCR3) antagonists: Improving the selectivity of DPC168 by reducing central ring lipophilicity
Pruitt, James R.,Batt, Douglas G.,Wacker, Dean A.,Bostrom, Lori L.,Booker, Shon K.,McLaughlin, Erin,Houghton, Gregory C.,Varnes, Jeffrey G.,Christ, David D.,Covington, Maryanne,Das, Anuk M.,Davies, Paul,Graden, Danielle,Kariv, Ilona,Orlovsky, Yevgeniya,Stowell, Nicole C.,Vaddi, Krishna G.,Wadman, Eric A.,Welch, Patricia K.,Yeleswaram, Swamy,Solomon, Kimberly A.,Newton, Robert C.,Decicco, Carl P.,Carter, Percy H.,Ko, Soo S.
, p. 2992 - 2997 (2008/02/05)
DPC168, a benzylpiperidine-substituted aryl urea CCR3 antagonist evaluated in clinical trials, was a relatively potent inhibitor of the 2D6 isoform of cytochrome P-450 (CYP2D6). Replacement of the cyclohexyl central ring with saturated heterocycles provid
